SecBot SecBot
SECBOTREPLAY Home › Report › ZYME

ZYME · Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting…

Zymeworks Inc. · PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET

Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed objective response rate in platinum-resistant ovarian cancer at doses of 6.4–9.6 mg/kg, with durable responses and a manageable safety profile. The data support advancing ZW191 into later-stage development for ovarian and endometrial cancers, where treatment options are limited.

  • ZW191 showed a 61% confirmed objective response rate (cORR) in platinum-resistant ovarian cancer at 6.4–9.6 mg/kg dose range.
  • Median progression-free survival was 7.6 months; median duration of response not reached, indicating durability.
  • Activity was observed regardless of FRα expression, expanding potential patient population.
  • Safety profile was manageable, with 55% grade ≥3 treatment-emergent adverse events (mostly neutropenia, anemia, thrombocytopenia).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access